EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit

Ensembl ID : ENSVVUG00000003844
Gene Symbol: GABRA1
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSVVUG00000023139
Gene Symbol: GABRA4
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha5 Subunit

Ensembl ID : ENSVVUG00000008787
Gene Symbol: GABRA5
3 Cross references
262 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit

Ensembl ID : ENSVVUG00000003850
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit

Ensembl ID : ENSVVUG00000003904
Gene Symbol: GABRB2
3 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Delta Subunit

Ensembl ID : ENSVVUG00000004685
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma1 Subunit

Ensembl ID : ENSVVUG00000023123
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma2 Subunit

Ensembl ID : ENSVVUG00000003824
Gene Symbol: GABRG2
3 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Pi Subunit

Ensembl ID : ENSVVUG00000002730
Gene Symbol: GABRP
3 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSVVUG00000023124
Gene Symbol: GABRA2
3 Cross references
253 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSVVUG00000029067
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSVVUG00000008833
Gene Symbol: GABRB3
3 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).